Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience☆
References (50)
Effect of anti-oestrogens on initiation of mammary cancer in the female rat
Eur J Cancer
(1971)Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata
Eur J Cancer
(1976)- et al.
Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model
Eur J Cancer
(1980) - et al.
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Bteast and Bowel Project B-24 randomised controlled trial
Lancet
(1999) - et al.
Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853
Lancet
(2000) Current concepts in the detection and treatment of the earliest of the early breast cancers
Cancer
(1970)- et al.
Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone
JAMA
(1978) - et al.
Intraductal carcinoma of the breast: Follow-up after biopsy only
Cancer
(1982) - et al.
Carcinoma in situ of the breast
Cancer
(1977) - et al.
Clinical significance of pre-invasive breast carcinoma
Cancer
(1980)
Duct carcinoma in situ
Cancer
(1982)
Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer
N Engl J Med
(1985)
Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer
N Engl J Med
(1993)
Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel project B-17
J Clin Oncol
(1998)
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-17: Intraductal carcinoma (duct carcinoma in situ)
Cancer
(1995)
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
J Natl Cancer Inst
(1996)
Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh
Lancet
(1987)
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptorpositive tumors
N Engl J Med
(1989)
Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer
Br J Cancer
(1988)
Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy
J Natl Cancer Inst
(1991)
New perspective on cancer of the contralateral breast: A marker for assessing tamoxifen as a preventive agent
J Natl Cancer Inst
(1991)
Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
J Natl Cancer Inst
(1998)
Lumpectomy and axillary dissection for breast cancer: Surgical, pathological, and radiation considerations
World J Surg
(1985)
Nonparametric estimation from incomplete observations
J Am Stat Assoc
(1958)
Evaluation of survival data and two new rank order statistics arising in its consideration
Cancer Chemother Rep
(1966)
Cited by (0)
- ☆
Supported by Public Health Service Grants No. U10-CA-12027, U10-CA-69651, U10-CA-37377, and U10-CA-69974 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.
Copyright © 2001 Published by Elsevier Inc.